Search titles, impact clusters, countries, organizations and the full text of every analysis.
21 stories found
Stanford, Harvard and UCLA-affiliated authors synthesize evidence across diagnostic, treatment-management and care-adjacent agent deployments. They find that current implementations remain concentrated in administrative workflows, although agents are beginning to appear throughout the clinical journey.
A few saved minutes can be worth taking seriously. A Nature Cancer study tested AI assistance with human verification for extracting immunotherapy-related adverse events from clinical notes. In its crossover exercise, annotation took less time. That is a concrete workflow result, not a claim that a chatbot can replace an oncology team. The design keeps the claim bounded: a small staff group worked with a limited set of notes, and the study came from one health system. A strict all-label agreement measure improved, but remained low in both conditions. The study did not establish better patient outcomes. Those qualifications do not erase the time saving; they tell us what kind of benefit was actually measured. I find this more useful than a vague promise to transform medicine. A specific task has a visible human checkpoint. The next question is whether the saved effort translates into something the service and its patients value: less administrative strain, more timely review or additional capacity. That requires measurement rather than assumption. There are tradeoffs worth watching. A suggested answer can anchor a reviewer, and faster annotation can create a larger queue of findings needing action. The downstream work must be counted alongside the time saved at the screen. Our morning research adds an important baseline: an earlier preprint described this same project. It is not a second independent replication. The constructive next step is external, prospective testing that keeps verification meaningful and evaluates what happens after a flag is raised. We can appreciate a useful result without asking it to prove more than it does.
If an AI overlay helps a surgeon identify anatomy, its uncertainty should be part of the conversation. A study of 47 neurosurgeons explored which explanations clinicians found useful when interpreting AI-supported surgical anatomy recognition. Certainty-focused displays were preferred over some alternative explanation approaches. The result is a useful design signal, not evidence that those displays make an operation safer. The supplied June preprint now has a peer-reviewed counterpart published in Scientific Reports on October 24. That changes the publication status, not the study design: it remains an international cross-sectional electronic survey using a still surgical image and illustrative segmentation. Participants considered numerical certainty, spatial certainty maps and other explanation methods. Preferences are important when building an interface people must understand under pressure, but liking an explanation is different from using it to catch an error. There is also a distinction between displaying a confidence score and proving that it is calibrated. A confident-looking interface can mislead if its apparent precision does not correspond to reliability. A better evaluation would ask whether clinicians reject incorrect suggestions, recognize unfamiliar cases and retain an independent view of the anatomy. Those are proposed next tests, not results this survey established. A separate, small first-in-human feasibility study from the same team offers a grounded reminder of deployment complexity: two of eight planned deployments failed before surgery because of configuration problems. It is neither independent replication nor a broad safety verdict. The constructive lesson is to design uncertainty and fallback into the workflow from the beginning. Surgeons are asking for information about the tool's limits. That is an invitation to build a more useful assistant, not an obstacle to progress.
If a hospital tells you a clinician checks the AI, that sounds reassuring. A new peer-reviewed review asks the question hidden inside that reassurance: what happens when the automated advice is wrong? Its evidence concerns the performance of the human-and-system combination, not simply whether a person was present in the workflow. The review includes 46 reports representing 41 independent cohort clusters, with 40 core cohorts. In four heterogeneous real-world computerized ECG studies, the pooled proportion of erroneous interpretations not corrected or recognized was 26.6%, with a very wide 95% confidence interval of 6.4% to 65.6%. That is not a failure rate for all clinicians, modern chatbots or clinical AI. The newer AI and language-model studies were too different to combine in the same way. Patient-level adverse events appeared in only one retrospective cohort. For a patient, the implication is neither to distrust every tool nor to assume a professional signature settles the safety question. For an institution, it is to test the actual review process using deliberately incorrect recommendations before relying on it. Does the reviewer see the underlying evidence? Can they disagree without friction? Is there enough time to check? Those are proposed design tests, not interventions this review proves will work everywhere. The study supports a harder standard for oversight: demonstrate error interception in the intended setting, then keep watching real outcomes.
A doctor wondering which treatment to choose is a more consequential scene than an AI acing a diagnostic quiz. A new JAMA study analyzed 271 million questions submitted by 952,008 verified US clinicians to OpenEvidence between January 2024 and June 2026. Among physicians' queries, 33.1% concerned treatment and management, while 13.9% concerned diagnosis. More than half were categorized as clinical decision-making. Monthly active users rose from 355 to 703,265 over the study period, though that is growth on one platform, not a count of all US clinicians using AI. The authors say early-career physicians and nonprocedural specialties used it disproportionately. That should change the evaluation agenda. A tool can score well on diagnostic vignettes and still give weak medication guidance, omit a contraindication or misread an evolving guideline. The study did not examine the answers, clinical decisions or patient outcomes, and it could not tell whether a question was asked at the bedside or in preparation. Its topic labels came from a model, with a small clinician validation sample, and several authors disclosed employment at the platform. Those limits do not make the usage pattern unimportant; they make independent treatment-focused testing more urgent. The next studies should compare AI-assisted and usual-care decisions on real treatment tasks, measure errors as well as speed, and ask whether patients are better off. For now, the accurate headline is not that AI treats patients. It is that clinicians are increasingly asking it treatment questions before we have strong public evidence for those answers.
The UK government has accepted all 44 recommendations from an independent commission on regulating AI in healthcare. That is a policy commitment, not 44 rules that have already taken effect or proof that an AI product improves patients' health. The most concrete change today is the opening of Phase 3 of the MHRA's AI Airlock, a regulatory sandbox focused on post-market surveillance and how AI-enabled devices behave after deployment. The commission's central critique is that one-time assessment is not enough for technology that changes, drifts or meets different patients and clinical workflows. The government promises draft guidance by December 2026 on managing changes to AI-enabled medical devices and a full implementation roadmap by spring 2027. It also plans future consultation on how devices are classified. The application terms expose an important implementation question: participation has no fee, but applicants currently fund their own studies and data access, and testing in real settings remains in a shadow pathway rather than directly informing patient decisions. That can be a sensible safety design; it may also be harder for smaller developers to finance, although participation data do not yet show exclusion. Patients should ask whether monitoring will detect unequal performance, how clinicians will report failures, who can pause an update, and whether results will be public. Healthcare AI's promise is real enough to warrant testing. The hard work starts after a policy announcement: measure outcomes over time, name the accountable institution, and show what happens when the system changes under care.
A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.
Ambient AI scribes are spreading faster than the evidence needed to govern them. A new British Dental Journal literature review searched research published from January 2015 through December 2025, screened 3,036 records, and included 57 studies. Only three focused on dentistry. The systems can reduce documentation burden and may improve burnout measures, but fluent notes can conceal omissions, substitutions, and hallucinations that are harder to notice precisely because the prose reads well. In one dental speech-recognition study, an experimental system reached a 3.7 percent word-error rate and the strongest commercial product reached 5.4 percent, yet clinically meaningful mistakes remained, including changing “16 hours” to “10 minutes.” Across wider healthcare research cited by the review, one analysis found hallucinations in 1.47 percent of note sentences and omissions corresponding to 3.45 percent of transcript sentences. Those figures are not universal error rates; studies used different systems, specialties, and definitions. The severity evidence is still sobering: 44 percent of hallucinated sentences and 16.7 percent of omissions in that study were classified as capable of major harm. Human review reduced clinically significant errors from 63.6 percent to 7.8 percent in another cited study, but that shifts clinicians from writers to editors and potential liability sinks. Patient attitudes also depend on disclosure. Favorability toward ambient documentation fell when people received fuller information about how it works. The technology may genuinely return attention to the patient. Its success will depend on whether saved typing time becomes careful verification time rather than disappearing from the workflow.
Anthropic says a campaign of roughly 950 Claude agents found a previously uncharacterized biological system while mining public DNA-sequence data. Over about 21 hours and 210 million tokens, the agents gathered more than 200,000 reverse transcriptases, selected roughly 3,500 candidate systems, and narrowed the field to about 20 detailed reports. One agent noticed evenly spaced non-coding DNA repeats beside an unusual reverse transcriptase and an accessory gene in bacteriophages. Anthropic calls the system array-associated reverse transcriptases, or ART. The arrangement resembles CRISPR arrays, and early experiments indicate that the ART array is expressed as distinct short RNAs. That does not establish a new gene-editing tool. Anthropic states that ART's natural function is unknown, the underlying reverse transcriptase had appeared in earlier studies, and all laboratory experiments were performed by human scientists. The work is a preprint from an Anthropic research group and its own Bay Area lab, so independent replication and peer review remain essential. The important signal is methodological. Agents can expand genome mining by running hundreds of searches and critiques in parallel, while expert judgment and physical experiments decide which machine-generated hypotheses survive. If replicated, the productivity gain may come less from replacing biologists than from making the neglected parts of enormous public datasets searchable at a new scale.
A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.
The BBC reports that Anthropic blocked what may have been an attempt to use Claude for biological-weapons work. Anthropic's own September threat report gives the claim important boundaries. The company says it identified five case studies that could support biological-weapons development, including efforts involving gain-of-function work, avian-influenza adaptation planning, and attempts to evade regional controls. It banned accounts, strengthened safeguards, and shared relevant intelligence. Yet the company also says intent can be difficult to distinguish from legitimate dual-use research and that these cases do not prove an imminent AI-uplifted biological threat. That ambiguity is the core governance problem. Biology is a field where ordinary research concepts, planning steps, and literature analysis can be beneficial in one context and dangerous in another. A model may only need to reduce friction at a few critical stages to change the risk, even if it cannot independently create a weapon. Providers therefore need more than content filters. They need identity and access controls, sequence-aware monitoring, escalation for combinations of suspicious tasks, expert review, and rapid information sharing that protects legitimate science. Public reporting should also distinguish observed behavior, inferred intent, and demonstrated capability. Sensational certainty can damage research and hide the real lesson: dual-use misuse is already appearing in provider enforcement data, while its actual uplift and intent remain hard to measure.
Reuters reports that Anthropic has opened a research preview of the Model Hardware Standard, a shared specification for AI agents to operate physical devices used in scientific research and advanced manufacturing. MHS replaces bespoke integrations with standardized drivers and simple read and write commands, making devices discoverable to agents and exposing characteristics, adjustable settings, and enforced safety limits. Anthropic says labs can connect equipment in hours or minutes instead of weeks or months, while agents coordinate microscopes, liquid handlers, robotic arms, cameras, and laser systems across round-the-clock workflows. Early partner demonstrations include autonomous experiment adjustments and a quantum-computing laser controller that reportedly recovered its lock 99.3 percent of the time in a blind test. These are research-preview results, not a general safety guarantee. Anthropic says current models still have spatial and physical reasoning limitations and require expert oversight. Before open sourcing the standard, the preview should prove that device permissions remain narrow, unsafe states fail closed, logs cannot be altered by the acting agent, and humans retain a physical stop outside the network path.
A Nature Health systematic review of 330 medical-AI studies found that patient factors are rarely integrated across the full AI lifecycle and are heavily concentrated in late validation. Among the papers reviewed, 70.6 percent assessed patient satisfaction and 69.4 percent perceived benefits, but only 16.7 percent examined trust and 10.9 percent safety. Patient factors were assessed during validation in 89.4 percent of cases, while only 3.9 percent incorporated them during design and development. The analysis covers reported studies rather than new patient-level data, and the included research spans different applications and methods, so the percentages should not be treated as a single performance score for medical AI. The pattern is still consequential. A patient can report a satisfying interaction without understanding the system, trusting the institution that uses it, or being protected from error and harm. If trust, safety, usability, adherence, privacy, and patient characteristics arrive only after a model is built, the product may optimize for a population and workflow that never existed outside the laboratory.
A peer-reviewed Nature Health Perspective argues that consumer health AI is shifting from an information tool toward control of the care pathway. Major platforms are connecting health-oriented language models to medical records, appointment booking, pharmacy fulfilment, payments, and clinical workflows. The paper examines ChatGPT Health, Amazon Health AI, Ant Group's Afu, and Claude for Healthcare, and says public-health importance increasingly depends on platform integration depth rather than model performance alone. Deeper integration could help patients complete care, especially where services are fragmented or resource constrained. It can also concentrate triage power and create new asymmetries in data and operational control. The proposed accountability framework focuses on evaluation, procurement, routing transparency, data governance, and exit options. Regulators should follow the entire pathway: who interprets symptoms, ranks providers, sees the record, takes payment, and lets a patient leave.
A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.
WCAX reports that schools are testing AI-driven tutoring and automated grading to personalize learning while navigating academic integrity and the possible loss of human connection. The tradeoff cannot be reduced to adoption versus prohibition. A tutor that gives immediate feedback may expand access, and an assistant that handles routine grading may return time to teachers. The same system can make confident mistakes, expose student data, reward answer production over understanding, or shift professional judgment from an educator to a vendor. Schools need evidence about learning outcomes, not only engagement or time saved. They also need clear rules for disclosure, privacy, age-appropriate use, independent assessment, and the teacher's right to override the tool. The safest classroom is not the one with the least technology. It is the one where AI strengthens human teaching without replacing the struggle, trust, and relationship through which students actually learn.
A Nature Medicine commentary argues that medical AI urgently needs a rigorous, task-based framework for defining and measuring “superintelligence.” Existing benchmarks can reward narrow performance without showing that a system can improve care across real clinical work, making headline claims potentially misleading. The proposal shifts attention from whether a model beats a score to which medical tasks are tested, against which human comparison, under what conditions, and with what evidence of patient benefit and safety.
The authors argue that AI’s effect on aggregate healthcare spending will not follow automatically from technical productivity gains: payment incentives, organizational priorities, implementation capacity, and management decisions will determine whether efficiency improvements lower costs, increase service volume, or are absorbed by providers. Even organizations financially rewarded for reducing expenditures may struggle to translate AI-supported productivity into lower spending because of internal workflows, professional incentives, and institutional dynamics.
University of Chicago and University of Wisconsin researchers randomized 180 hospitalized patients identified by a real-time machine-learning score as being at elevated risk of acute kidney injury. Triggering an early structured nephrology consultation did not significantly reduce peak creatinine changes, acute kidney injury, mortality, readmission, or other major outcomes; many specialist recommendations were not followed by the treating teams.
The paper introduces Biomni, a general-purpose biomedical agent that can search literature, formulate hypotheses, select datasets and specialized tools, write analytical code, interpret results, and propose subsequent experiments within an integrated workflow. Stanford reports that a prototype is already used by more than 10,000 laboratories; in one example, it processed over 450 wearable-health files and generated plausible findings in 40 minutes, compared with an estimated 60 or more hours of human work.
This Oxford-led npj Digital Medicine review screened 17,463 records and included 140 empirical studies of human-AI collaboration in healthcare from January 2015 through October 2025. It finds that the evidence base is concentrated in diagnostic interpretation, while triage, therapeutic, administrative, and system-level workflows remain thinner; it also notes that AI benefits depend heavily on task fit, workflow integration, training, and calibrated trust.